The Finvera Stock News Headlines API provides realtime coverage of US stock news and the objective reason behind a stocks movement beyond it's normal intraday range.

  • Actionable “Why”: catalyst + catalyst_created flags for AI-generated context.

  • Clean security mapping: securities[] with ticker, exchcode, FIGI, shareclassfigi, marketsector.

  • Smart associations: Related press_releases, ratings, transcripts.

  • Logos & branding: logo_exists, logo_thumbnail_url for UI cards.

  • Timestamps & IDs: id, news_id, created_at, updated_at for lineage & de-dup.

  • Brokerage price alerting

  • News cards in brokerage & research apps

  • Backtests filtered by type (e.g., gainers, losers) or catalyst presence

curl --request GET \
  --url https://api.finvera.news/news/api/v1/news
curl --request GET \
  --url https://api.finvera.news/news/api/v1/news

Note: Fields omitted with ... for brevity.

{
  "data": [
    {
      "catalyst": "Oncolytics Biotech shares are trading higher after the company appointed Jared Kelly as CEO and announced promising clinical data for pelareorep in cancer treatments.",
      "catalyst_created": true,
      "created_at": "2025-06-11T22:50:22.325207Z",
      "headline": "Oncolytics Biotech Stock Rises Amidst New Leadership and Promising Clinical Data",
      "id": 3908,
      "logo_exists": true,
      "logo_thumbnail_url": "https://d31b1il8wjbsxw.cloudfront.net/svg_16_9_thumbnail_v2/BBG001SDGSF3.svg",
      "news_id": "514a640a-d427-4fb2-baa4-8b947f8edf02",
      "on_all_tickers": true,
      "on_entities": true,
      "securities": [
        {
          "figi": "BBG000DVS826",
          "name": "Oncolytics Biotech, Inc. Common Shares",
          "MIC": "",
          "exchcode": "XNAS",
          "ticker": "ONCY",
          "compositefigi": "BBG000DVS826",
          "securitytype": "CS",
          "marketsector": "stocks",
          "shareclassfigi": "BBG001SDGSF3"
        },
        {
          "figi": "BBG000DVS826",
          "name": "ONCOLYTICS BIOTECH INC",
          "MIC": "",
          "exchcode": "US",
          "ticker": "ONCY",
          "compositefigi": "BBG000DVS826",
          "securitytype": "Common Stock",
          "marketsector": "Equity",
          "shareclassfigi": "BBG001SDGSF3"
        }
      ],
      "share_class_figi": "BBG001SDGSF3",
      "ticker": "ONCY",
      "type": "gainers",
      "updated_at": "2025-06-11T22:50:22.325215Z"
    }
  ],
  "message": "news fetched successfully"
}
{
  "data": [
    {
      "catalyst": "Oncolytics Biotech shares are trading higher after the company appointed Jared Kelly as CEO and announced promising clinical data for pelareorep in cancer treatments.",
      "catalyst_created": true,
      "created_at": "2025-06-11T22:50:22.325207Z",
      "headline": "Oncolytics Biotech Stock Rises Amidst New Leadership and Promising Clinical Data",
      "id": 3908,
      "logo_exists": true,
      "logo_thumbnail_url": "https://d31b1il8wjbsxw.cloudfront.net/svg_16_9_thumbnail_v2/BBG001SDGSF3.svg",
      "news_id": "514a640a-d427-4fb2-baa4-8b947f8edf02",
      "on_all_tickers": true,
      "on_entities": true,
      "securities": [
        {
          "figi": "BBG000DVS826",
          "name": "Oncolytics Biotech, Inc. Common Shares",
          "MIC": "",
          "exchcode": "XNAS",
          "ticker": "ONCY",
          "compositefigi": "BBG000DVS826",
          "securitytype": "CS",
          "marketsector": "stocks",
          "shareclassfigi": "BBG001SDGSF3"
        },
        {
          "figi": "BBG000DVS826",
          "name": "ONCOLYTICS BIOTECH INC",
          "MIC": "",
          "exchcode": "US",
          "ticker": "ONCY",
          "compositefigi": "BBG000DVS826",
          "securitytype": "Common Stock",
          "marketsector": "Equity",
          "shareclassfigi": "BBG001SDGSF3"
        }
      ],
      "share_class_figi": "BBG001SDGSF3",
      "ticker": "ONCY",
      "type": "gainers",
      "updated_at": "2025-06-11T22:50:22.325215Z"
    }
  ],
  "message": "news fetched successfully"
}

The catalyst color headlines are generated using AI and reviewed by humans prior to publishing.